SK50699A3 - Methods and compositions for delivery and expression of interferon-'alpha' nucleic acids - Google Patents

Methods and compositions for delivery and expression of interferon-'alpha' nucleic acids Download PDF

Info

Publication number: SK50699A3
Authority: SK; Slovakia
Prior art keywords: interferon; promoter; alpha; expression; tissue
Prior art date: 1996-10-18

Application number

SK506-99A

Other languages

English (en)

Slovak (sk)

Inventor

Tattanahalli L Nagabhushan

Deba P Saha

Original Assignee

Canji Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-18

Filing date

1997-10-16

Publication date

2000-05-16

1997-10-16 Application filed by Canji Inc filed Critical Canji Inc

2000-05-16 Publication of SK50699A3 publication Critical patent/SK50699A3/sk

Links

239000000203 mixture Substances 0.000 title claims description 40
150000007523 nucleic acids Chemical class 0.000 title claims description 31
238000000034 method Methods 0.000 title claims description 24
108020004707 nucleic acids Proteins 0.000 title claims description 24
102000039446 nucleic acids Human genes 0.000 title claims description 24
230000014509 gene expression Effects 0.000 title description 46
210000001519 tissue Anatomy 0.000 claims description 59
108010047761 Interferon-alpha Proteins 0.000 claims description 46
102000006992 Interferon-alpha Human genes 0.000 claims description 45
239000013598 vector Substances 0.000 claims description 30
210000004185 liver Anatomy 0.000 claims description 8
239000013603 viral vector Substances 0.000 claims description 6
210000002307 prostate Anatomy 0.000 claims description 4
230000028327 secretion Effects 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 2
241000701161 unidentified adenovirus Species 0.000 claims description 2
239000002773 nucleotide Substances 0.000 claims 1
125000003729 nucleotide group Chemical group 0.000 claims 1
210000004027 cell Anatomy 0.000 description 68
108090000623 proteins and genes Proteins 0.000 description 39
102000004169 proteins and genes Human genes 0.000 description 15
108020004414 DNA Proteins 0.000 description 14
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 14
206010028980 Neoplasm Diseases 0.000 description 12
239000013612 plasmid Substances 0.000 description 12
201000011510 cancer Diseases 0.000 description 10
239000003623 enhancer Substances 0.000 description 10
239000013604 expression vector Substances 0.000 description 10
239000002502 liposome Substances 0.000 description 10
108010050904 Interferons Proteins 0.000 description 9
108090000765 processed proteins & peptides Proteins 0.000 description 9
229940079322 interferon Drugs 0.000 description 8
230000008685 targeting Effects 0.000 description 8
102000014150 Interferons Human genes 0.000 description 7
108091028043 Nucleic acid sequence Proteins 0.000 description 6
239000003098 androgen Substances 0.000 description 6
108060001084 Luciferase Proteins 0.000 description 5
108010072866 Prostate-Specific Antigen Proteins 0.000 description 5
108010026331 alpha-Fetoproteins Proteins 0.000 description 5
102000013529 alpha-Fetoproteins Human genes 0.000 description 5
208000006454 hepatitis Diseases 0.000 description 5
231100000283 hepatitis Toxicity 0.000 description 5
230000000968 intestinal effect Effects 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
108010079944 Interferon-alpha2b Proteins 0.000 description 4
102100038358 Prostate-specific antigen Human genes 0.000 description 4
241000700605 Viruses Species 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
238000001415 gene therapy Methods 0.000 description 4
206010073071 hepatocellular carcinoma Diseases 0.000 description 4
230000003211 malignant effect Effects 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
230000002103 transcriptional effect Effects 0.000 description 4
108010088751 Albumins Proteins 0.000 description 3
102000009027 Albumins Human genes 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
108020004638 Circular DNA Proteins 0.000 description 3
241000206602 Eukaryota Species 0.000 description 3
239000005089 Luciferase Substances 0.000 description 3
206010060862 Prostate cancer Diseases 0.000 description 3
208000000236 Prostatic Neoplasms Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000000427 antigen Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000013613 expression plasmid Substances 0.000 description 3
239000012091 fetal bovine serum Substances 0.000 description 3
210000003494 hepatocyte Anatomy 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000003446 ligand Substances 0.000 description 3
230000036210 malignancy Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
108020005029 5' Flanking Region Proteins 0.000 description 2
101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
102000004420 Creatine Kinase Human genes 0.000 description 2
108010042126 Creatine kinase Proteins 0.000 description 2
102000001039 Dystrophin Human genes 0.000 description 2
108010069091 Dystrophin Proteins 0.000 description 2
108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000711549 Hepacivirus C Species 0.000 description 2
241000700721 Hepatitis B virus Species 0.000 description 2
241000724709 Hepatitis delta virus Species 0.000 description 2
101000827785 Homo sapiens Alpha-fetoprotein Proteins 0.000 description 2
101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 description 2
102100040018 Interferon alpha-2 Human genes 0.000 description 2
208000009869 Neu-Laxova syndrome Diseases 0.000 description 2
108010077850 Nuclear Localization Signals Proteins 0.000 description 2
102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
206010061494 Rhinovirus infection Diseases 0.000 description 2
229930182558 Sterol Natural products 0.000 description 2
108010022394 Threonine synthase Proteins 0.000 description 2
108020004440 Thymidine kinase Proteins 0.000 description 2
230000001028 anti-proliverative effect Effects 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
102000005936 beta-Galactosidase Human genes 0.000 description 2
108010005774 beta-Galactosidase Proteins 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
102000004419 dihydrofolate reductase Human genes 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
210000005003 heart tissue Anatomy 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
102000046101 human AFP Human genes 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
230000010354 integration Effects 0.000 description 2
230000003902 lesion Effects 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002609 medium Substances 0.000 description 2
244000005700 microbiome Species 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
231100000915 pathological change Toxicity 0.000 description 2
230000036285 pathological change Effects 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000001177 retroviral effect Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
235000002639 sodium chloride Nutrition 0.000 description 2
239000000243 solution Substances 0.000 description 2
150000003432 sterols Chemical class 0.000 description 2
235000003702 sterols Nutrition 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
239000002753 trypsin inhibitor Substances 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
108020003589 5' Untranslated Regions Proteins 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
208000003200 Adenoma Diseases 0.000 description 1
206010001233 Adenoma benign Diseases 0.000 description 1
UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
101710186708 Agglutinin Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010059313 Anogenital warts Diseases 0.000 description 1
101710081722 Antitrypsin Proteins 0.000 description 1
108010074051 C-Reactive Protein Proteins 0.000 description 1
102100032752 C-reactive protein Human genes 0.000 description 1
101100478314 Caenorhabditis elegans sre-1 gene Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
102000004410 Cholesterol 7-alpha-monooxygenases Human genes 0.000 description 1
108090000943 Cholesterol 7-alpha-monooxygenases Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
102000012422 Collagen Type I Human genes 0.000 description 1
108010022452 Collagen Type I Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
102100028652 Gamma-enolase Human genes 0.000 description 1
101710103262 Glandular kallikrein Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
102000001398 Granzyme Human genes 0.000 description 1
108060005986 Granzyme Proteins 0.000 description 1
102100030385 Granzyme B Human genes 0.000 description 1
208000037262 Hepatitis delta Diseases 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
101100153048 Homo sapiens ACAA1 gene Proteins 0.000 description 1
101500025164 Homo sapiens Alpha-1-microglobulin Proteins 0.000 description 1
101000942118 Homo sapiens C-reactive protein Proteins 0.000 description 1
101100273713 Homo sapiens CD2 gene Proteins 0.000 description 1
101001009603 Homo sapiens Granzyme B Proteins 0.000 description 1
101000854886 Homo sapiens Immunoglobulin iota chain Proteins 0.000 description 1
101710146024 Horcolin Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102100020744 Immunoglobulin iota chain Human genes 0.000 description 1
102100040019 Interferon alpha-1/13 Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
101710189395 Lectin Proteins 0.000 description 1
102000036243 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Human genes 0.000 description 1
108010002481 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
101710179758 Mannose-specific lectin Proteins 0.000 description 1
101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000713869 Moloney murine leukemia virus Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
208000031662 Noncommunicable disease Diseases 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
102100027384 Proto-oncogene tyrosine-protein kinase Src Human genes 0.000 description 1
101710122944 Proto-oncogene tyrosine-protein kinase Src Proteins 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
102000040739 Secretory proteins Human genes 0.000 description 1
108091058545 Secretory proteins Proteins 0.000 description 1
241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
241000710960 Sindbis virus Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
208000005485 Thrombocytosis Diseases 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
102000003848 Uteroglobin Human genes 0.000 description 1
108090000203 Uteroglobin Proteins 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
230000009858 acid secretion Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000000910 agglutinin Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000001475 anti-trypsic effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
108010087173 bile salt-stimulated lipase Proteins 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
210000003443 bladder cell Anatomy 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000009702 cancer cell proliferation Effects 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
229940096422 collagen type i Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
-1 cyclic anhydride Chemical class 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
239000004062 cytokinin Substances 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000835 fiber Substances 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
102000028718 growth factor binding proteins Human genes 0.000 description 1
108091009353 growth factor binding proteins Proteins 0.000 description 1
210000002768 hair cell Anatomy 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
208000029570 hepatitis D virus infection Diseases 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000002998 immunogenetic effect Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000013546 insoluble monolayer Substances 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
210000004216 mammary stem cell Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
239000000693 micelle Substances 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
231100000782 microtubule inhibitor Toxicity 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
230000035773 mitosis phase Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000036457 multidrug resistance Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000000849 parathyroid Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229930029653 phosphoenolpyruvate Natural products 0.000 description 1
DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
239000000523 sample Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Plant Pathology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)

SK506-99A 1996-10-18 1997-10-16 Methods and compositions for delivery and expression of interferon-'alpha' nucleic acids SK50699A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US73381596A	1996-10-18	1996-10-18
PCT/US1997/017928 WO1998017801A1 (en)	1996-10-18	1997-10-16	METHODS AND COMPOSITIONS FOR DELIVERY AND EXPRESSION OF INTERFERON-α NUCLEIC ACIDS

Publications (1)

Publication Number	Publication Date
SK50699A3 true SK50699A3 (en)	2000-05-16

Family

ID=24949214

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK506-99A SK50699A3 (en)	1996-10-18	1997-10-16	Methods and compositions for delivery and expression of interferon-'alpha' nucleic acids

Country Status (20)

Country	Link
EP (2)	EP1591528A3 (id)
JP (2)	JP2001502540A (id)
KR (1)	KR20000049243A (id)
AR (1)	AR013618A1 (id)
AU (1)	AU4808097A (id)
BR (1)	BR9712362A (id)
CA (1)	CA2269100A1 (id)
CZ (1)	CZ131699A3 (id)
DE (1)	DE932679T1 (id)
ES (1)	ES2136583T1 (id)
HU (1)	HUP9904219A2 (id)
ID (1)	ID24500A (id)
IL (1)	IL129387A0 (id)
NO (1)	NO991839L (id)
NZ (1)	NZ335134A (id)
PL (1)	PL332856A1 (id)
SK (1)	SK50699A3 (id)
TR (1)	TR199901190T2 (id)
WO (1)	WO1998017801A1 (id)
ZA (1)	ZA979295B (id)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9912925D0 (en) *	1999-06-03	1999-08-04	Angeletti P Ist Richerche Bio	Adenoviral vectors encoding interferon and their use in gene therapy
US8058248B2 (en) *	2001-04-26	2011-11-15	The United States Of America As Represented By The Secretary Of Agriculture	Foot and mouth disease virus vaccine comprising interferons
US7217796B2 (en)	2002-05-24	2007-05-15	Schering Corporation	Neutralizing human anti-IGFR antibody
JP2007510434A (ja)	2003-11-12	2007-04-26	シェーリング　コーポレイション	多重遺伝子発現のためのプラスミドシステム
PE20050928A1 (es)	2003-11-21	2005-11-08	Schering Corp	Combinaciones terapeuticas de anticuerpo anti-igfr1
CA2548100C (en) *	2003-12-10	2015-03-24	Canji, Inc.	Methods and compositions for treatment of interferon-resistant tumors
EP2283831A3 (en)	2004-12-03	2013-10-23	Merck Sharp & Dohme Corp.	Biomakers for pre-selection of patients for anti-IGF1R therapy
US8454948B2 (en)	2006-09-14	2013-06-04	Medgenics Medical Israel Ltd.	Long lasting drug formulations
US9155749B2 (en)	2006-09-14	2015-10-13	Medgenics Medical Israel Ltd.	Long lasting drug formulations
WO2008101349A1 (en)	2007-02-23	2008-08-28	Her Majesty The Queen, In Right Of Canada, As Repesented By The Minister Of National Defence	Recombinant viral vectors for prevention and protection against alphavirus infection
WO2010142017A1 (en)	2009-06-09	2010-12-16	Defyrus, Inc .	Administration of interferon for prophylaxis against or treatment of pathogenic infection
CN103260649A (zh)	2010-06-15	2013-08-21	迈德詹尼克斯医疗以色列有限公司	长效药物制剂
WO2018178215A1 (en)	2017-03-31	2018-10-04	Accanis Biotech F&E Gmbh & Co Kg	Prevention and treatment of non-melanoma skin cancer (nmsc)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4238778C2 (de) *	1992-11-12	1995-11-02	Max Delbrueck Centrum	Vektor zur Expression von therapeutisch relevanten Genen
US5631236A (en) *	1993-08-26	1997-05-20	Baylor College Of Medicine	Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
EP1637608B1 (en) *	1993-10-25	2009-07-22	CANJI, Inc.	Recombinant adenoviral vector and methods of use
US5830686A (en) *	1994-01-13	1998-11-03	Calydon	Tissue-specific enhancer active in prostate
DE4407859C1 (de) *	1994-03-04	1995-03-02	Max Planck Gesellschaft	Vektor für die leberspezifische Gentherapie
JP4216350B2 (ja) *	1994-09-19	2009-01-28	大日本住友製薬株式会社	動物細胞感染用の組換えｄｎａウイルスベクター
US5789244A (en) *	1996-01-08	1998-08-04	Canji, Inc.	Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

1997
- 1997-10-16 ES ES97910794T patent/ES2136583T1/es active Pending
- 1997-10-16 KR KR1019990703347A patent/KR20000049243A/ko not_active Withdrawn
- 1997-10-16 EP EP05013342A patent/EP1591528A3/en not_active Withdrawn
- 1997-10-16 BR BR9712362-5A patent/BR9712362A/pt not_active Application Discontinuation
- 1997-10-16 HU HU9904219A patent/HUP9904219A2/hu unknown
- 1997-10-16 SK SK506-99A patent/SK50699A3/sk unknown
- 1997-10-16 NZ NZ335134A patent/NZ335134A/en unknown
- 1997-10-16 PL PL97332856A patent/PL332856A1/xx unknown
- 1997-10-16 JP JP10519400A patent/JP2001502540A/ja not_active Withdrawn
- 1997-10-16 IL IL12938797A patent/IL129387A0/xx unknown
- 1997-10-16 WO PCT/US1997/017928 patent/WO1998017801A1/en not_active Ceased
- 1997-10-16 CZ CZ991316A patent/CZ131699A3/cs unknown
- 1997-10-16 TR TR1999/01190T patent/TR199901190T2/xx unknown
- 1997-10-16 CA CA002269100A patent/CA2269100A1/en not_active Abandoned
- 1997-10-16 AU AU48080/97A patent/AU4808097A/en not_active Abandoned
- 1997-10-16 ZA ZA9709295A patent/ZA979295B/xx unknown
- 1997-10-16 ID IDW990218D patent/ID24500A/id unknown
- 1997-10-16 EP EP97910794A patent/EP0932679A1/en not_active Ceased
- 1997-10-16 DE DE0932679T patent/DE932679T1/de active Pending
- 1997-10-17 AR ARP970104830A patent/AR013618A1/es not_active Application Discontinuation
1999
- 1999-04-16 NO NO991839A patent/NO991839L/no not_active Application Discontinuation
2008
- 2008-08-20 JP JP2008212260A patent/JP2008301832A/ja active Pending

Also Published As

Publication number	Publication date
AU4808097A (en)	1998-05-15
EP1591528A3 (en)	2005-11-16
ID24500A (id)	2000-07-20
IL129387A0 (en)	2000-02-17
PL332856A1 (en)	1999-10-25
TR199901190T2 (xx)	1999-07-21
JP2001502540A (ja)	2001-02-27
EP1591528A2 (en)	2005-11-02
KR20000049243A (ko)	2000-07-25
BR9712362A (pt)	1999-08-31
DE932679T1 (de)	2000-03-09
NO991839D0 (no)	1999-04-16
AR013618A1 (es)	2001-01-10
CA2269100A1 (en)	1998-04-30
NO991839L (no)	1999-06-15
EP0932679A1 (en)	1999-08-04
CZ131699A3 (cs)	1999-07-14
JP2008301832A (ja)	2008-12-18
HUP9904219A2 (hu)	2000-12-28
WO1998017801A1 (en)	1998-04-30
ES2136583T1 (es)	1999-12-01
ZA979295B (en)	1998-04-20
NZ335134A (en)	2001-05-25

Publication	Publication Date	Title
US20240000968A1 (en)	2024-01-04	Mesothelioma Gene Therapy
US20080166373A1 (en)	2008-07-10	METHODS AND COMPOSITIONS FOR DELIVERY AND EXPRESSION OF INTERFERON-alpha NUCLEIC ACIDS
JP2008301832A (ja)	2008-12-18	インターフェロン−α核酸の送達および発現のための方法および組成物
JP4219335B2 (ja)	2009-02-04	インターフェロンβのような分泌タンパク質をコードする遺伝子を使用する治療のための方法および組成物
US20040110131A1 (en)	2004-06-10	Thrombospondin-1 type 1 repeat polypeptides
Narumi et al.	1998	Adenovirus vector-mediated perforin expression driven by a glucocorticoid-inducible promoter inhibits tumor growth in vivo
MXPA99003563A (en)	2000-04-24	METHODS AND COMPOSITIONS FOR DELIVERY AND EXPRESSION OF INTERFERON-&agr;NUCLEIC ACIDS
AU2004201252A1 (en)	2004-04-29	Methods and compositions for delivery and expression of interferon- alpha nucleic acids
KR19980701695A (ko)	1998-06-25	미오신 중쇄 sm1 이소폼 단백질을 암호화하는 dna를 벡터 dna에 삽입시킨 재조합 dna, 전기 재조합 dna가 도입된 미생물 및 재조합 dna를 포함하는 동맥경화증 치료제
AU2007242949A1 (en)	2008-01-10	Methods and compositions for delivery and expression of interferon-alpha nucleic acids
CN1240480A (zh)	2000-01-05	运送和表达干扰素－α核酸的方法和组合物
AU3521101A (en)	2001-06-28	Methods and compositions for delivery and expression of interferon-alpha nucleic acids
AU2002224002B2 (en)	2007-04-05	Promoters exhibiting endothelial cell specificity and methods of using same
EP1679375A1 (en)	2006-07-12	Methods and compositions for cancer therapies using genes encoding interferon-beta
HK1095525B (en)	2011-10-14	Methods and compositions for treatment of interferon-resistant tumors
MXPA00005516A (es)	2001-12-04	Composiciones y metodos para inducir la expresion de genes
HK1155956A (en)	2012-06-01	Methods and compositions for treatment of interferon-resistant tumors